I-MED appoints Natasha Toohey as Chief Executive Officer

I-MED appoints Natasha Toohey as Chief Executive Officer

I-MED appoints Natasha Toohey as Chief Executive Officer

Jardine Matheson ("Jardines") and I-MED Radiology Network ("I-MED") today announce the appointment of Natasha Toohey as Chief Executive Officer of I-MED. Natasha will begin engaging with I-MED colleagues in February to support a smooth transition, before formally taking up her role on 1 March.

Natasha is a highly accomplished healthcare executive with more than two decades of leadership spanning public and private health services, clinical operations, large-scale transformation, strategy, governance, and innovation. She is currently Chief Operating Officer of Epworth HealthCare, Victoria's largest not-for-profit private hospital group, which she joined in February 2022.

At Epworth, Natasha oversees a network of hospitals that deliver approximately 240,000 admissions and 150,000 procedures annually, with a workforce of over 8,000 employees and 4,000 visiting medical officers. During her tenure, she has led significant growth and operational transformation, delivering substantial improvements in patient experience, workforce engagement, and service innovation.

Before joining Epworth, Natasha spent more than a decade with Western Health, including four years as Executive Director of Operations, where she led complex, multi-site healthcare operations, delivering major service growth, technology and capital expansion programmes.

Natasha Toohey, incoming CEO of I-MED, said:

“I am delighted to be joining I-MED at an exciting time in its development. I-MED is a leader in its field, with an outstanding clinical reputation and an important role in patient care across Australia, New Zealand and the United States. I look forward to working with I-MED’s team of doctors and staff, and to building on the company’s strong foundations as I-MED continues to expand its diagnostic imaging services and strengthen its contribution to improving healthcare outcomes for patients and referring clinicians.”

Lincoln Pan, CEO of Jardine Matheson, said:

“We are delighted to welcome Natasha to I-MED. Natasha brings extensive experience in healthcare delivery, with a strong record of driving growth, organisational excellence, operational improvement and transformation. She is recognised for her collaborative leadership style with medical practitioners and her teams and for her commitment to high-quality and safe patient care. As shareholder, our objective for I-MED at Jardines is to pursue a long-term strategy that builds a bigger and better business and Natasha’s successful leadership track record in large complex medical systems will further enhance the terrific company I-MED already is.”  

“Jardines and the Board of I-MED would like to thank Clare Battellino for her continued leadership as acting CEO – she has made important contributions to I-MED over many years, including during this transitional period, and the Board looks forward to Clare’s ongoing counsel and leadership for I-MED.”

George Savvides, Chair of I-MED, said:

Natasha is well placed to lead I-MED through its next phase of development while maintaining the high standards of service and care that underpin the trust I-MED has built with patients, clinicians and partners. I-MED’s partnerships with hospitals, medical specialists, and medical practitioners are paramount to our future success and Natasha’s deep health sector experience building collaborative, sustainable partnerships will lift I-MED’s capabilities to serve our referral and hospital partners and importantly, attract and retain the best Radiologists and clinical teams to I-MED.” 

Natasha began her career in physiotherapy before moving into increasingly senior healthcare management and operational roles. She holds a Master of Public Health from Monash University and a Bachelor of Physiotherapy from the University of Melbourne and is a graduate of the Australian Institute of Company Directors.

Jardine Matheson acquired I-MED in October 2026, marking its first major investment since its transition to an investment company in 2025. More details are available [here].

[ENDS]